Publications by authors named "J P GEIGER"
Synaptic mechanisms that contribute to human memory consolidation remain largely unexplored. Consolidation critically relies on sleep. During slow wave sleep, neurons exhibit characteristic membrane potential oscillations known as UP and DOWN states.
View Article and Find Full Text PDFArticle Synopsis
- - Lassa virus (LASV) leads to hundreds of thousands of infections in Western Africa annually, with about 20% progressing to Lassa fever, a serious disease that has a high fatality rate.
- - Currently, there are no approved vaccines or treatments for Lassa fever, but researchers have been working on recombinant LASVs (rLASVs) that show promising results as vaccines in animal models.
- - The new vaccine candidate, rLASV/IGR-CD, demonstrated high safety and effectiveness in guinea pigs, offering complete protection against lethal LASV exposure and advancing the development of a live-attenuated vaccine for Lassa fever.
Isolation and Analysis of Mitochondrial Small RNAs from Rat Liver Tissue and HepG2 Cells.
Methods Mol Biol
November 2024
The presence of non-coding RNAs, such as microRNAs (miRNAs), in mitochondria has been reported by several studies. The biological roles and functions of these mitochondrial miRNAs ("mitomiRs") have not been sufficiently characterized, but the mitochondrial localization of miRNAs has recently gained significance due to modified mitomiR-populations in certain states of diseases. Here, we describe the isolation and analysis of mitochondrial RNAs from rat liver tissue and HepG2 cells.
View Article and Find Full Text PDFThe developing mammalian heart undergoes an important metabolic shift from glycolysis towards mitochondrial oxidation that is critical to support the increasing energetic demands of the maturing heart. Here, we describe a new mechanistic link between mitochondria and cardiac morphogenesis, uncovered by studying mitochondrial citrate carrier (SLC25A1) knockout mice. Slc25a1 null embryos displayed impaired growth, mitochondrial dysfunction and cardiac malformations that recapitulate the congenital heart defects observed in 22q11.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effectiveness of enfortumab vedotin (EV), an antibody-drug conjugate targeting nectin-4, in patients with unresectable recurrent/metastatic head and neck cancer (HNC) who have previously received other therapies.
- In a phase II trial involving 46 patients, the objective response rate (ORR) was 23.9%, with a disease control rate (DCR) of 56.5%, while median progression-free survival (PFS) and overall survival (OS) were 3.9 and 6.0 months, respectively.
- Adverse events were primarily alopecia, fatigue, and peripheral sensory neuropathy, with 34.8% of patients experiencing